How does scavenger receptor B1 polymorphism (rs4238001) affect the progression of Hepatitis C patients with persistent viral responses?

Aim: Scavenger receptor B1 (SR-B1) is an important glycoprotein that plays an important role in the entry of hepatitis C virus (HCV) tohepatocyte. SR-B1 also acts as a modulator in many situations, such as both the natural and adaptive immune system. The effectsof HCV on entry to hepatocyte and response to treatment in SR-B1 mutations were investigated in many studies performed before.We aimed to investigate the effects of SR-B1 polymorphism on liver in patients with noncirrhotic HCV who received pegylatedinterferon + ribavirin treatment and had persistent viral response (SVR).Material and Methods: We included naive, non-cirrhosis patients diagnosed with HCV in our clinic between 2008 and 2009. Wemonitored approximately 53 patients form whom we obtained SVR after treatment and followed up regularly for at least twice a yearfor ten years. We evaluated ultrasonography, laboratory parameters and calculated non-invasive fibrosis scores (APRI and FIB-4).Results: A total of 91% of patients were genotype 1b and 9% were genotype 1a. 2 patients developed cirrhosis in 4th and 6th yearof their follow-up. One of these patients had Wild type SR-B1 rs4238001 (Gly2Ser) (GG) genotype and the other had heterozygousSR-B1 (GA) genotype. We detected no cirrhosis in none of the other 51 patients. We found improvement in APRI and FIB4 scoresduring follow-up in patients with both wild type and heterozygous SR-B1 genotype. It was more pronounced in the heterozygous SRB1 group (pretreatment and 10th year values, respectively 0.82±0.65, 0.38±0.24 for APRI, 1.79±1.12, 1.31±0.65 for FIB-4) (p< 0.05).Conclusion: The improvement of noninvasive fibrosis scores of SR-B1 mutations in non-cirrhotic HCV patients with SVR was moreprominent in the group with heterozygous mutations. Although no difference was detected between SR-B1 mutations in terms of riskof cirrhosis progression and HCC development, larger studies are needed in this direction.

PDF

___

1. PrabhuDas MR, Baldwin CL, Bollyky PL, et al. A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease. J Immunol 2017;15:198:3775-89.
2. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001;7:853- 7.
3. Guo L, Song Z, Li M, et al. Scavenger receptor BI protects against septic death through its role in Modulating inflammatory response. J Biol Chem 2009;284:19826-34.
4. Eck MV. Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J. Lipid Res 2008;49:136-46.
5. Shen WJ, Asthana S, Kraemer FB, et al. Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function. J Lipid Res 2018;59:1114-31.
6. Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474:208-11.
7. Li XA, Titlow WB, Jackson BA, et al. High density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J Biol Chem 2002;277:11058-63.
8. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-16.
9. van der Meer AJ, Veldt BJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
10. Abergel A, Darcha C, Chevallier M, et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 2004;16:1219-27.
11. Casado JL, Esteban MA, Banon S, et al. Fibrosis regression explains differences in outcome in HIV-/ HCV-coinfected patients with cirrhosis after sustained virological response. Dig Dis Sci 2015;60:3473-81.
12. Chu CY, Cheng CH, Chen HL, et al. Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response. J Formos Med Assoc 2019;118:1129-37.
13. Pradat P, Tillmann HL, Sauleda S, et al. HENCORE Group. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liverrelated complications. J Viral Hepat 2007;14:556-63.
14. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807-20.
15. Zarski JP, Sturm N, Desmorat H, et al. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy:a randomized study. Liver Int 2010;30:1049-58.
16. Cordie A, Salama A, El-Sharkawy M, et al. Comparing the efficiency of Fib-4, Egy-score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. J Med Virol 2018;90:1106-11.
17. Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol 2016;64:773-80.
18. European Association for Study of Liver, Asociacion Latino americana para el Estudio del Higado. EASLALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracing DNA from human nucleated cells. Nucleic Acids Res 1988;16:12-5.
20. Acton S, Osgood D, Donoghue M, et al. Association of Polymorphisms at the SR-BI Gene Locus With Plasma Lipid Levels and Body Mass Index in a White Population. Arterioscler Thromb Vasc Biol 1999;19:1734-43.
21. Westhaus S, Deest M, Nguyen ATX, et al. Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. J Hepatol 2017;67:237-45.
22. Nafari M, Irani S, Vaziri F, et al. Correlation of CD81 and SCARB1 polymorphisms on virological responses in Iranian patients with chronic hepatitis C virus genotype 1. Infect Genet Evol 2018;62:296-303.
23. Hsu CS, Hsu SJ, Liu WL, et al. Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy Sci Rep 2016;6:32303.
24. Vercauteren K, Van Den Eede N, Mesalam AA, et al. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 2014;60:1508-18.
25. Meuleman P, Catanese MT, Verhoye L, et al. A human monoclonal antibody targeting SR-BI precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012;55:364-72.
26. Dieperink E, Pocha C, Thuras P, et al. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci 2014;59:872-80.
27. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
28. Kawamura Y, Arase Y, Ikeda K, et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferontreated hepatitis C patients. Am J Med 2010;123:951- 6.
29. Moon C, Jung KS, Kim DY, et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015;60:573-81.
30. George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009;49:729-38.